Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

What Is the Jevons Paradox and What Does It Mean for Micron and Sandisk Investors After Google's Revolutionary AI Breakthrough?

View original at nasdaq.com
What Is the Jevons Paradox and What Does It Mean for Micron and Sandisk Investors After Google's Revolutionary AI Breakthrough? Key Points Google's memory-compression algorithm caused Micron and Sandisk stocks to plunge…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q3 revenue forecast of $33.5 billion, representing growth of 260% year over year and 40% quarter over quarter

    60% confidence
  • 10 best stocks for investors to buy now identified, and Alphabet wasn't one of them

    60% confidence
  • Developments like TurboQuant are positive, as performance improvements will drive further adoption of AI and strengthen demand for key components such as memory chips

    60% confidence
  • Gross margin expected to increase by 660 basis points, from 74.4% to about 81%

    60% confidence
  • Reiterated outperform (buy) ratings on both Micron and Sandisk

    60% confidence
  • TurboQuant reduces memory usage by at least 6x and delivers up to 8x speedup, all with zero accuracy loss, redefining AI efficiency

    60% confidence
  • Gross margin expected to reach 65.9% at midpoint, nearly triple last year's 22.5%

    60% confidence
  • More efficient use of resources reduces their costs, ultimately increasing demand for them

    60% confidence
  • TurboQuant will enable larger LLMs, faster inference and better tokenomics, spurring more spending

    60% confidence
  • Stock Advisor's total average return is 926%, outperforming the S&P 500's 185%

    60% confidence
  • Adjusted diluted earnings per share expected to reach roughly $19.15, a 10-fold increase

    60% confidence
  • Q3 revenue forecast of $4.6 billion at midpoint of guidance, representing 171% growth

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com